Abstract

In the article “The role of radiotherapy in neoadjuvant treatment of patients with operable pancreatic head cancer” results of the combined neoadjuvant treatment of operable pancreatic cancer were presented. Patients, suffering from pancreatic cancer (n = 40) were randomized into two arms and compared arm one: intra-arterial chemotherapy + radiation therapy + operation (n = 20) vs arm two: intra-arterial chemotherapy + operation (n = 20).

Neoadjuvant radiation therapy was performed with 2 fractions per day 2 Gy each with 4-6 hours between them 5 days a week up until summary dose of 50 Gy. Neoadjuvant radiation therapy with a double fractioning per day had proven to be safe and effective. Arm 1 had statistically verified lower postoperative pancreatitis frequency and chances to develop fistulas, higher number of second degree pathomorphosis

outcomes, as well as life expectancy median.

Keywords: Radiation Therapy; Pancreatic Cancer; Double Day Fractioning

References

1. Rawla P., et al. “Epidemiology of pancreatic cancer: global trends, etiology and risk factors”. World Journal of Oncology1 (2019): 10.
2. Edited by AD Kaprin., et al. State of cancer care to the population of Russia in 2017. M: MNIOI P.A. Herzen branch of the Federal State Budgetary Institution "National Medical Research Center of Radiology" of the Ministry of Health of Russia (2018): 236.
3. IA Pokataev., et al. “Practical recommendations for drug treatment of pancreatic cancer”. Malignant Tumors: RUSSCO Practice Guidelines 27 (2020): 492-506.
4. Ducreux M., et al. “Cancer of the Pancreas: ESMO clinical practise guidelines”. Supplements - Annals of Oncology 5 (2015): 56-68.
5. Tempero MA., et al. “Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology”. Journal of the National Comprehensive Cancer Network4 (2021): 439-457.
6. Pan L., et al. “Survival benefits of neoadjuvant chemo (radio) therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis”. World Journal of Surgical Oncology1 (2020): 1-13.
7. Han D., et al. “Analysis of radiotherapy impact on survival in resected stage I/II pancreatic cancer patients: a population-based study”. BMC Cancer1 (2021): 1-11.
8. Cloyd JM., et al. “Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomized controlled trials”. Journal of Clinical Medicine4 (2020): 1129.
9. Versteijne E., et al. “Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial”. Journal of Clinical Oncology16 (2020): 1763-1773.
10. Pusceddu S., et al. “Comparative effectiveness of gemcitabine plus nab-paclitaxel and FOLFIRINOX in the first-line setting of metastatic pancreatic cancer: a systematic review and meta-analysis”. Cancers 11.4 (2019): 484.
11. DA Granov., et al. “Assessment of the safety of intra-arterial chemotherapy with gemcitabine and oxaliplatin in the combined treatment of adenocarcinoma of the pancreatic head”. Annals of Surgical Hepatology2 (2017): 54-59.
12. Qiu B., et al. “Transcatheter arterial infusion for pancreatic cancer: a 10-year National Cancer Center experience in 115 patients and literature review”. Abdominal Radiology8 (2019): 2801-2808.
13. EF Lushnikov. “Therapeutic pathomorphosis of tumors”. Pathological diagnosis of human tumors book. Ed.byA.V. Kraevsky, D.S. Smolyannikova, M. Sarkisova: Medicine (1993.): 560.
14. AN Gerasimov. “Medical statistics”. M .: Medical Information Agency (2007): 475.
15. Kaplan EL and P Meier. “Nonparametric estimation from incomplete observations”. Journal of the American Statistical Association 53 (1958): 457-481.
16. Brierley James D., et al. “TNM classification of malignant tumours”. John Wiley and Sons (2017).
17. Tsai S., et al. “Evolution of the management of resectable pancreatic cancer”. Journal of Oncology Practice9 (2016): 772-778.
18. Seshacharyulu P., et al. “Biological determinants of radioresistance and their remediation in pancreatic cancer”. Biochimica et Biophysica Acta (BBA)1 (2017): 69-92.
19. Han D., et al. “Analysis of radiotherapy impact on survival in resected stage I/II pancreatic cancer patients: a population-based study”. BMC cancer1 (2021): 1-11.
20. AV Kozlov., et al. “Arterial chemoembolization in patients with locally advanced pancreatic cancer”. Herald of Surgery1 (2018): 31-36.
21. LI Korytova., et al. “Possibilities of conformal radiation therapy in the treatment of patients with locally advanced pancreatic cancer”. Russian Biotherapeutic Journal1 (2017): 44-45.
22. Peng JS., et al. “Pathologic tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer”. Hepatobiliary and Pancreatic Diseases International4 (2019): 373-378.
23. AV Pavlovsky., et al. “Influence of perioperative intra-arterial selective chemotherapy on the period of recurrence of ductal adenocarcinoma of the pancreatic head after pancreatoduodenal resection”. Annals of Surgical Hepatology3 (2018):14-22.
24. Michael Yan., et al. “A Comparison of Hypofractionated and Twice-Daily Thoracic Irradiation in Limited-Stage Small-Cell Lung Cancer: An Overlap-Weighted Analysis”. Cancers 13 (2021): 2895.
25. John J Coen., et al. “Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712—A Randomized Phase II Trial”. Journal of Clinical Oncology1 (2019): 44-52.

Citation

Citation: LI Korytova., et al. “The Role of Radiotherapy in Neoadjuvant Treatment of Patients with Operable Pancreatic Head Cancer”. Acta Scientific Gastrointestinal Disorders 4.11 (2021): 36-42.

Copyright

Copyright: © 2021 LI Korytova., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.